These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 16751711)

  • 1. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease.
    Després JP
    J Endocrinol Invest; 2006; 29(3 Suppl):77-82. PubMed ID: 16751711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
    Després JP; Lemieux I; Alméras N
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is visceral obesity the cause of the metabolic syndrome?
    Després JP
    Ann Med; 2006; 38(1):52-63. PubMed ID: 16448989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
    Lee M; Aronne LJ
    Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among primary care physicians, the general population and patients at risk--the Shape of the Nations survey.
    Smith SC; Haslam D
    Curr Med Res Opin; 2007 Jan; 23(1):29-47. PubMed ID: 17261236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care].
    Scholze J; Lilienthal W; Bramlage P
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():103-10. PubMed ID: 17955787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and strategies in managing cardiometabolic risk.
    Repas TB
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S4-11. PubMed ID: 17784529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The progression of cardiovascular risk to cardiovascular disease.
    Rosin BL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for modifying cardiometabolic risk factors.
    Aronne LJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
    Haffner SM
    Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system in the regulation of cardiometabolic risk factors.
    Bellocchio L; Vicennati V; Cervino C; Pasquali R; Pagotto U
    Am J Cardiol; 2007 Dec; 100(12A):7P-17P. PubMed ID: 18154746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health.
    Cota D
    Diabetes Metab Res Rev; 2007 Oct; 23(7):507-17. PubMed ID: 17683024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing cardiometabolic risk: an evolving approach to patient care.
    Watson K
    Crit Pathw Cardiol; 2007 Mar; 6(1):5-14. PubMed ID: 17667880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.
    Bays HE; González-Campoy JM; Bray GA; Kitabchi AE; Bergman DA; Schorr AB; Rodbard HW; Henry RR
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):343-68. PubMed ID: 18327995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes mellitus: a high-risk condition for cardiovascular disease irrespective of the different degrees of obesity.
    Song SH; Hardisty CA
    QJM; 2008 Nov; 101(11):875-9. PubMed ID: 18776208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity.
    McLaughlin T; Abbasi F; Lamendola C; Reaven G
    Arch Intern Med; 2007 Apr; 167(7):642-8. PubMed ID: 17420421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fat distribution and metabolism].
    Després JP; Lemieux I; Tchernof A; Couillard C; Pascot A; Lemieux S
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):209-14. PubMed ID: 11452212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.